8-K: Current report filing
Published on August 8, 2003
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 20549
_____________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: August 7, 2003
ACCESS PHARMACEUTICALS, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-9314 83-0221517
- ---------------------------- ------------- -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
2600 Stemmons Frwy. Suite 176, Dallas, TX 75207
-----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (214) 905-5100
--------------
Not applicable
-------------------------------------------------------------
(Former name or former address; if changed since last report)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Access Pharmaceuticals, Inc. Press Release, dated August 6, 2003.
Item 9. Regulation FD Disclosure.
The following information is furnished pursuant to Item 12, "Disclosure
of Results of Operations and Financial Condition."
Access Pharmaceuticals, Inc. issued a press release on August 6, 2003,
a copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced that on August 12, 2003
it will report its financial results for the second quarter ended June 28,
2003. It also announced that it will hold a conference call on August 12,
2003 to discuss the positive financial results, including that it has achieved
its objective of being cash flow neutral, and other product developments.
This information shall not be deemed to be "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934 and shall not be
deemed to be incorporated by reference in any filing under the Securities
Act of 1933.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ACCESS PHARMACEUTICALS, INC.
Dated: August 7, 2003 By: /s/ Stephen B. Thompson
-----------------------
Stephen B. Thompson
Vice President and Chief Financial
Officer (Principal Financial and
Accounting Officer)
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Press Release, dated August 6, 2003